Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich
Russian and AZ COVID vaccines in combo trial
AstraZeneca plc (LSE:AZN; NASDAQ:AZN) will begin by year-end a clinical trial of its AZD1222, developed with the University of Oxford, in combination with the adenovirus serotype 26 (Ad26) component of Sputnik V from the Direct Investment Fund and N.F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology. Ad26 is a human virus and AZD1222 uses a chimpanzee adenovirus vector; and application of different vectors in prime vs. boost immunizations could avoid dampened SARS-CoV-2 immunity caused by immune responses against the first vaccine component's vector.
Lilly’s tirzepatide meets in Phase III diabetes trial
Eli Lilly and Co. (NYSE:LLY) said tirzepatide (LY3298176) led to significant reductions in A1c and body weight from baseline in the Phase III SURPASS-1 trial to treat adults with Type II diabetes. The co-agonist of GLP-1 and GIP was dosed once-weekly for 40 weeks. Detailed data will be presented at the American Diabetes Association’s meeting in June. ...